SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

TWG is trending due to news of a projected net profit for FY25, sparking significant interest and volume. The community is actively discussing potential price targets, with some aiming for substantial gains, while others urge caution due to the stock's volatility. Similar to other recent runners, TWG's low float is contributing to the amplified price action.

Cemtrex, Inc. engages in the provision of solutions in the technology industry. It operates through the following segments: Security, Industrial Services, and Cemtrex Corporate. The Security segment provides end-to-end security solutions to meet corporate, industrial, and governmental security challenges. The Industrial Services segment offers single-source expertise and services for rigging, millwrighting, in plant maintenance, equipment erection, relocation, and disassembly to diversified customers. The Cemtrex Corporate segment refers to the holding company of the other two segments. The company was founded on April 27, 1998 and is headquartered in Hauppauge, NY.

Cemtrex Inc.

Cemtrex ($CETX) is trending with significant volume, sparking discussions of a potential short squeeze similar to $SMX and $TGL. Community members are focused on holding strong through volatility, with many eyeing a move past key resistance levels and anticipating a surge in after-hours trading. The stock's low float and recent price action are fueling speculation of substantial gains.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana's stock is surging following the announcement of its inclusion in the S&P 500, fueling enthusiasm among investors. Community members are actively discussing the potential for continued gains, while others express concerns about the company's valuation and long-term prospects, drawing comparisons to past market bubbles and questioning the fundamentals.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune ($ALT) is trending as anticipation builds around upcoming 48-week data, with community members actively discussing the potential for statistically significant fibrosis improvement. Bullish sentiment is fueled by speculation that positive data could lead to a buyout, while some traders are closely watching technical indicators and potential market reactions. The focus remains on Altimmune's drug Pemvidutide and its potential in the MASH treatment landscape.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Recent news of a potential deal with Warner Bros. Discovery has sparked significant debate around NFLX's future, with community members discussing the financial implications of the deal and potential regulatory hurdles. Some traders are focusing on technical indicators like RSI and identifying potential support levels, while others speculate on alternative scenarios and the impact of Paramount's competitive bid. The community is actively weighing the potential benefits and risks associated with the acquisition, with opinions divided on whether it will ultimately drive long-term value for Netflix.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

Wave Life Sciences is trending due to encouraging early data for their obesity drug, WVE-007, which showed fat reduction and lean mass preservation. Community discussions revolve around the potential offering price and the drug's promise in the competitive weight loss market, with some drawing comparisons to GLP-1s. Analysts have raised price targets, citing the drug's potential to rival existing treatments.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros Discovery is trending amid reports of a potential takeover battle, with Paramount making an all-cash offer to challenge Netflix's existing deal. Community chatter revolves around which bid will ultimately prevail and deliver the most value to WBD shareholders. Some traders speculate about a bidding war, while others focus on regulatory hurdles and potential impacts on the broader media landscape.

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc - ADR

Structure Therapeutics ($GPCR) is trending following positive topline ACCESS data for its oral GLP-1 candidate, aleniglipron, driving significant volume and a large price increase. Community discussions revolve around the drug's weight loss efficacy compared to competitors, its safety profile, and potential for acquisition by larger pharmaceutical companies. Analysts are weighing in with price target reiterations and buy ratings, contributing to the stock's momentum.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as holders express strong conviction and a sense of community, emphasizing the "We're All Gonna Make It" ethos. The community highlights locked liquidity and organic growth, suggesting a solid foundation. Conversations revolve around WAGMI's potential for significant gains as a Solana-based meme coin.

Treasure Global, Inc. engages in the provision of payment solutions. The firm created an online-to-offline (O2O) e-commerce platform business model offering consumers and merchants instant rebates and affiliate cashback programs. It operates through the ZCITY Platform and Customized Software Development Service segments. The company was founded by Kok Pin Tan on March 20, 2020 and is headquartered in New York, NY.

Treasure Global Inc

Treasure Global Inc. (TGL) is trending due to community speculation about another potential short squeeze, reminiscent of previous high-flying stocks. The stock's volatility and past performance, including a significant price surge earlier in the year, are fueling discussions, with traders weighing the risks and opportunities for quick gains, while some caution against bagholding.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$RPTX Excerpts taken from Repare’s Annual Report, 10-Q, over the last three (3) years; 
 
2             “In October 2021, we received notification from BMS of their option exercise for two (2) druggable targets directed at a single synthetic lethal lesion . . . “ 
l.               “In fiscal 2022, Bristol-Myers Squibb waived its rights to exercise options for druggable targets directed at two separate lesions” 
2             “In fiscal 2023, BMS exercised its option for a druggable target and also waived its rights to exercise an option for another druggable target” 
1                 “In March 2024, BMS exercised its one remaining option to in-license an undruggable target for a combined total of five druggable targets and one undruggable target over the course of the collaboration 
 
To summarize, BMS exercised their option on three (3) targets and waived their rights to option exercise on three (3) targets. So is BMS preparing to in-license and start clinical trials on three drugs sometime soon?

StockTwits Web

Repare Therapeutics Inc

 Excerpts taken from Repare’s Annual Report, 10-Q, over the last three (3) years; 
 
2             “In October 2021, we received notification from BMS of their option exercise for two (2) druggable targets directed at a single synthetic lethal lesion . . . “ 
l.               “In fiscal 2022, Bristol-Myers Squibb waived its rights to exercise options for druggable targets directed at two separate lesions” 
2             “In fiscal 2023, BMS exercised its option for a druggable target and also waived its rights to exercise an option for another druggable target” 
1                 “In March 2024, BMS exercised its one remaining option to in-license an undruggable target for a combined total of five druggable targets and one undruggable target over the course of the collaboration 
 
To summarize, BMS exercised their option on three (3) targets and waived their rights to option exercise on three (3) targets. So is BMS preparing to in-license and start clinical trials on three drugs sometime soon?

Stephen

… and now a fourth target has been exercised as per page 13, Q2, 10-K 
 
’In June 2025, the BMS agreement was amended to enable Bristol-Myers Squibb to exercise an additional option or another drug level target’